Filing summary: Organovo Holdings, Inc.
Reporting-period note: The supplied filing is Organovo Holdings, Inc.’s Form 10-Q for the quarter ended September 30, 2013, filed November 8, 2013. This does not match the request metadata identifying “Vivosim Labs, INC.” and “2013 Q2.” The company’s fiscal year ends March 31, so this is its second fiscal quarter of fiscal 2014.
Business context and reporting period
Organovo was a development-stage company developing functional 3D human tissues for drug discovery, biological research, and potential therapeutic applications. It said it had not generated significant revenue from its planned principal operations. The filing presents the three and six months ended September 30, 2013, compared with the corresponding 2012 periods. Amounts below are in U.S. dollars; financial statement amounts are generally in millions unless stated otherwise.
Financial performance and position
| Metric | Three months ended September 30 | Six months ended September 30 |
|---|---|---|
| Revenue | 2013: $0.023 million; 2012: $0.469 million | 2013: $0.129 million; 2012: $0.728 million |
| Operating expenses | 2013: $5.625 million; 2012: $4.087 million | 2013: $9.465 million; 2012: $5.796 million |
| Operating loss | 2013: $5.602 million; 2012: $3.618 million | 2013: $9.336 million; 2012: $5.068 million |
| Net income (loss) | 2013: $(10.386) million; 2012: $38.478 million | 2013: $(14.157) million; 2012: $3.093 million |
| Cash used in operating activities | Not separately presented for the quarter | 2013: $6.256 million; 2012: $4.159 million |
Product revenue was zero in both comparable periods. Revenue was principally collaboration and grant revenue; the filing reports no clear positive gross margin measure for these periods. At September 30, 2013, cash and cash equivalents were $53.357 million, total current assets $53.735 million, current liabilities $2.940 million, working capital approximately $50.8 million, and total assets $54.898 million. Total liabilities were $2.956 million, including $0.795 million of warrant liabilities and $0.020 million of capital lease obligations. Accumulated development-stage deficit was $80.522 million.
Material changes versus prior comparable periods
- Revenue fell 95% year over year for the quarter and 86% for the six-month period. Management attributed the decline to a decreasing payment schedule under existing collaborations and no material revenue yet from newer agreements.
- Operating expenses increased 37% for the quarter and 64% for six months, reflecting staff growth, higher research activity, stock-based compensation, and public-company, listing, and offering costs. Headcount rose from 26 to 36 full-time employees; R&D staff rose from 17 to 24.
- Six-month operating cash use increased by approximately $2.1 million year over year, which management attributed mainly to lower revenue and higher operating expenses.
- Net results were significantly affected by noncash remeasurement of warrant liabilities. The 2012 quarter included $42.252 million of income from a decrease in warrant fair value; the 2013 quarter recorded $4.787 million of expense from an increase. For the six-month comparisons, the corresponding effects were $8.315 million of income in 2012 and $4.811 million of expense in 2013.
- In August 2013, the company sold 10.35 million shares at $4.50 per share, receiving approximately $43.4 million net proceeds. Cash increased from $15.628 million at March 31 to $53.357 million at September 30.
Outlook, risks, contingencies, and unusual items
- Management said available cash and expected collaboration receipts were sufficient to fund operations as currently planned for at least the next 12 months. It cautioned that additional capital may be needed and may not be available on favorable terms; a funding shortfall could require delaying, reducing, or ending programs or relinquishing technology rights.
- Warrant liabilities were valued using Level 3 inputs and a Monte Carlo model. The company warned that changes in share price, volatility, remaining term, and other assumptions could cause significant quarter-to-quarter fair-value swings.
- The company disclosed a dispute with Spencer Trask Ventures concerning fees and alleged confidentiality breaches. The company contested the claims, had not accrued a loss because it considered a loss not probable or estimable, and said an unfavorable outcome could materially adversely affect its business, liquidity, or financial condition.
- Operating lease commitments totaled approximately $1.411 million. A subsequent-event letter of intent proposed expanding the company’s San Diego premises; terms had not been finalized.
- The company reported no material changes to previously disclosed risk factors, no off-balance-sheet arrangements, and effective disclosure controls. Management noted the inherent limitations of control systems.
Important facts for investors to verify
- Confirm the issuer and period: the filing is for Organovo Holdings, Inc., not Vivosim Labs, and covers the quarter ended September 30, 2013.
- Review the August share offering, use of proceeds, share-count growth, and potential dilution from outstanding options and warrants.
- Assess whether collaboration revenue can grow enough to support the company’s expanding research and administrative costs.
- Track operating cash burn against management’s stated 12-month funding horizon and any need for further financing.
- Review developments and potential financial exposure in the Spencer Trask dispute, and the assumptions underlying warrant-liability valuations.